Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 299, Issue 4, 2010, Pages

  Morris, Jill K ^a   Bomhoff, Gregory L ^a   Stanford, John A ^a,b   Geiger, Paige C ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Diabetes; Dopamine; Insulin resistance; Striatum; Substantia nigra

Indexed keywords

GLUCOSE; INSULIN; OXIDOPAMINE; ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DOPAMINE; FAT INTAKE; FENTON'S REAGENT; GLUCOSE BLOOD LEVEL; HYDROGEN PEROXIDE; IRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE EXACERBATION; FAST MUSCLE; FAT INTAKE; GLUCOSE TRANSPORT; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LOCOMOTION; MEDIAL FOREBRAIN BUNDLE; MUSCLE ATROPHY; NERVE DEGENERATION; NONHUMAN; OBESITY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SUBSTANTIA NIGRA; ANIMAL; BLOOD; CHEMICALLY INDUCED; EATING; EPIDIDYMIS; FISCHER 344 RAT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLISM; MOUSE; NEOSTRIATUM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIETARY FATS; DOPAMINE; EATING; EPIDIDYMIS; GLUCOSE TOLERANCE TEST; HYDROGEN PEROXIDE; INSULIN; INSULIN RESISTANCE; IRON; MALE; MICE; MUSCLE, SKELETAL; NEOSTRIATUM; NERVE DEGENERATION; NEURONS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, INBRED F344; SUBSTANTIA NIGRA; SYMPATHOLYTICS;

EID: 77957575432     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00449.2010     Document Type: Article

References (59)

1. Abbott RD, Ross GW, White LR, Nelson JS, Masaki KH, Tanner CM, Curb JD, Blanchette PL, Popper JS, Petrovitch H. Midlife adiposity and the future risk of Parkinson's disease. Neurology 59: 1051-1057, 2002.
2. Altar CA, Marien MR, Marshall JF. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J Neurochem 48: 390-399, 1987.
3. Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, Petty RK. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 18: 1175-1177, 1993. (Pubitemid 23306353)
4. Barbeau A, Giguere R, Hardy J. [Clinical experience with tolbutamide in Parkinson's disease.]. Union Med Can 90: 147-151, 1961.
5. Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 991: 120-131, 2003.
6. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 21: 6853-6861, 2001.
7. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65: 135-172, 2001.
8. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North America 37: 635-646, viii-ix, 2008.
9. Borah A, Mohanakumar KP. L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation. Neurochem Int 56: 357-362.
10. Boyd AE, 3rd Lebovitz HE, Feldman JM. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alternation by L-Dopa. J Clin Endocrinol Metab 33: 829-837, 1971.
11. Bruce-Keller AJ, Keller JN, Morrison CD. Obesity and vulnerability of the CNS. Biochim Biophys Acta 1792: 395-400, 2009.
12. Cacho J, Sevillano J, de Castro J, Herrera E, Ramos MP. Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats. Am J Physiol Endocrinol Metab 295: E1269-E1276, 2008.
13. Cano P, Cardinali DP, Rios-Lugo MJ, Fernandez-Mateos MP, Reyes Toso CF, Esquifino AI. Effect of a high-fat diet on 24-hour pattern of circulating adipocytokines in rats. Obesity 17: 1866-1871, 2009.
14. Chess DJ, Khairallah RJ, O'Shea KM, Xu W, Stanley WC. A high-fat diet increases adiposity but maintains mitochondrial oxidative enzymes without affecting development of heart failure with pressure overload. Am J Physiol Heart Circ Physiol 297: H1585-H1593, 2009.
15. Choi JY, Jang EH, Park CS, Kang JH. Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. Free Radic Biol Med 38: 806-816, 2005.
16. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262: 689-695, 1993.
17. Davis JF, Tracy AL, Schurdak JD, Tschop MH, Lipton JW, Clegg DJ, Benoit SC. Exposure to elevated levels of dietary fat attenuates psychostimulant reward and mesolimbic dopamine turnover in the rat. Behav Neurosci 122: 1257-1263, 2008.
18. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 76: 149-155, 1985.
19. Downs CA, Jones LR, Heckathorn SA. Evidence for a novel set of small heat-shock proteins that associates with the mitochondria of murine PC12 cells and protects NADH:ubiquinone oxidoreductase from heat and oxidative stress. Arch Biochem Biophys 365: 344-350, 1999.
20. Escobedo J, Pucci AM, Koh TJ. HSP25 protects skeletal muscle cells against oxidative stress. Free Radic Biol Med 37: 1455-1462, 2004.
21. Fachinetto R, Burger ME, Wagner C, Wondracek DC, Brito VB, Nogueira CW, Ferreira J, Rocha JB. High fat diet increases the incidence of orofacial dyskinesia and oxidative stress in specific brain regions of rats. Pharmacol Biochem Behav 81: 585-592, 2005.
22. Fulton S, Pissios P, Manchon RP, Stiles L, Frank L, Pothos EN, Maratos-Flier E, Flier JS. Leptin regulation of the mesoaccumbens dopamine pathway. Neuron 51: 811-822, 2006.
23. Geiger BM, Haburcak M, Avena NM, Moyer MC, Hoebel BG, Pothos EN. Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity. Neuroscience 159: 1193-1199, 2009.
24. Gloire G, Legrand-Poels S, Piette J. NF-κB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72: 1493-1505, 2006.
25. Gupte AA, Bomhoff GL, Geiger PC. Age-related differences in skeletal muscle insulin signaling: the role of stress kinases and heat shock proteins. J Appl Physiol 105: 839-848, 2008.
26. Gupte AA, Bomhoff GL, Morris JK, Gorres BK, Geiger PC. Lipoic acid increases heat shock protein expression and inhibits stress kinase activation to improve insulin signaling in skeletal muscle from high-fat-fed rats. J Appl Physiol 106: 1425-1434, 2009.
27. Gupte AA, Bomhoff GL, Swerdlow RH, Geiger PC. Heat treatment improves glucose tolerance and prevents skeletal muscle insulin resistance in rats fed a high-fat diet. Diabetes 58: 567-578, 2009.
28. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 357: re13, 2006.
29. Hindle JV. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 39: 156-161, 2010.
30. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30: 842-847, 2007.
31. Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology 67: 1955-1959, 2006.
32. Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MB. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm 46: 297-314, 1995.
33. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 53 Suppl 3: S26-S36; discussion S36-S28, 2003.
34. Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL. Adult nutrient intake as a risk factor for Parkinson's disease. Int J Epidemiol 28: 1102-1109, 1999.
35. Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MB. Dopamine, 6-hydroxydopamine, iron, and dioxygen - their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta 1316: 160-168, 1996.
36. Lipman IJ, Boykin ME, Flora RE. Glucose intolerance in Parkinson's disease. J Chronic Dis 27: 573-579, 1974.
37. Martin HL, Teismann P. Glutathione-a review on its role and significance in Parkinson's disease. FASEB J 23: 3263-3272, 2009.
38. Moroz N, Tong M, Longato L, Xu H, de la Monte SM. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis 15: 29-44, 2008.
39. Morris JK, Zhang H, Gupte AA, Bomhoff GL, Stanford JA, Geiger PC. Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease. Brain Res 1240: 185-195, 2008.
40. Morrison CD, Pistell PJ, Ingram DK, Johnson WD, Liu Y, Fernandez- Kim SO, White CL, Purpera MN, Uranga RM, Bruce-Keller AJ, Keller JN. High-fat diet increases hippocampal oxidative stress and cognitive impairment in aged mice: Implications for decreased Nrf2 signaling. J Neurochem In press.
41. Palmiter RD. Is dopamine a physiologically relevant mediator of feeding behavior? Trends Neurosci 30: 375-381, 2007.
42. Park KJ, Gaynor RB, Kwak YT. Heat shock protein 27 association with the I κB kinase complex regulates tumor necrosis factor alpha-induced NF-κB activation. J Biol Chem 278: 35272-35278, 2003.
43. Pezzella A, d'Ischia M, Napolitano A, Misuraca G, Prota G. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. J Med Chem 40: 2211-2216, 1997.
44. Pistell PJ, Morrison CD, Gupta S, Knight AG, Keller JN, Ingram DK, Bruce-Keller AJ. Cognitive impairment following high fat diet consumption is associated with brain inflammation. J Neuroimmunol 219: 25-32, 2010.
45. Posey KA, Clegg DJ, Printz RL, Byun J, Morton GJ, Vivekanandan- Giri A, Pennathur S, Baskin DG, Heinecke JW, Woods SC, Schwartz MW, Niswender KD. Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 296: E1003-E1012, 2009.
46. Pressley JC, Louis ED, Tang MX, Cote L, Cohen PD, Glied S, Mayeux R. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 60: 87-93, 2003.
47. Seidell JC. Obesity, insulin resistance and diabetes - a worldwide epidemic. Brit J Nutr 83 Suppl 1: S5-S8, 2000.
48. Snyder AM, Connor JR. Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 1790: 606-614, 2009.
49. Stanford JA, Currier TD, Gerhardt GA. Acute locomotor effects of fluoxetine, sertraline, and nomifensine in young versus aged Fischer 344 rats. Pharmacol Biochem Behav 71: 325-332, 2002.
50. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 30: 244-250, 2007.
51. Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Cory-Slechta D. A Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res 873: 225-234, 2000.
52. Uranga RM, Bruce-Keller AJ, Morrison CD, Fernandez-Kim SO, Ebenezer PJ, Zhang L, Dasuri K, Keller JN. Intersection between metabolic dysfunction, high fat diet consumption, and brain aging. J Neurochem 114: 344-361, 2010.
53. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495, 2004.
54. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053, 2004.
55. Yokoyama H, Kuroiwa H, Yano R, Araki T. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci 29: 293-301, 2008.
56. Young DA, Uhl JJ, Cartee GD, Holloszy JO. Activation of glucose transport in muscle by prolonged exposure to insulin. Effects of glucose and insulin concentrations. J Biol Chem 261: 16049-16053, 1986.
57. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IκK. Science 293: 1673-1677, 2001.
58. Zhang X, Dong F, Ren J, Driscoll MJ, Culver B. High dietary fat induces NADPH oxidase-associated oxidative stress and inflammation in rat cerebral cortex. Exp Neurol 191: 318-325, 2005.
59. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13: 290-296, 1990.